



OPEN ACCESS

EDITED AND REVIEWED BY
Takahiro Kodama,
Osaka University, Japan

*CORRESPONDENCE
Jian-Hong Zhong
✉ zhongjianhong@gxmu.edu.cn

[†]These authors have contributed
equally to this work

RECEIVED 20 July 2025
ACCEPTED 08 August 2025
PUBLISHED 27 August 2025

CITATION

Peng N, Mao L-F, Su J-Y, Liu S-P, Ou J-J,
Chen S-C, Su Z, Li W-F, Yang F-Q,
Zhou Y-H, Li L and Zhong J-H (2025)
Correction: The efficacy and safety of
tislelizumab with or without tyrosine
kinase inhibitor as adjuvant therapy in
hepatocellular carcinoma with high-risk
of recurrence after curative resection.
Front. Immunol. 16:1669840.
doi: 10.3389/fimmu.2025.1669840

COPYRIGHT

© 2025 Peng, Mao, Su, Liu, Ou, Chen, Su, Li,
Yang, Zhou, Li and Zhong. This is an open-
access article distributed under the terms of
the [Creative Commons Attribution License](#)
(CC BY). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Correction: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection

Ning Peng^{1†}, Lin-Feng Mao^{1†}, Jia-Yong Su^{2†}, Shao-Ping Liu^{3†},
Jun-Jie Ou⁴, Shu-Chang Chen⁴, Ze Su⁵, Wen-Feng Li⁶,
Fu-Quan Yang⁶, Yong-Heng Zhou¹, Le Li² and
Jian-Hong Zhong ^{2*} on behalf of the GUIDANCE investigators

¹Hepatobiliary Surgery Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, ²Hepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning, China, ³Hepatobiliary Surgery Department, Guigang City People's Hospital, Guigang, China, ⁴General Surgery Department, The People's Hospital of Wuzhou, Wuzhou, China, ⁵Hepatobiliary Pancreatic Surgery Department, The First People's Hospital of Nanning, Nanning, China, ⁶Hepatobiliary and Pancreatic Surgery Department, The First People's Hospital of Yulin, Yulin, China

KEYWORDS

hepatocellular carcinoma, high-risk of recurrence, tislelizumab, recurrence-free survival, adjuvant therapy

A Correction on

The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection

By Peng N, Mao L-F, Su J-Y, Liu S-P, Ou J-J, Chen S-C, Su Z, Li W-F, Yang F-Q, Zhou Y-H, Li L and Zhong J-H (2025) *Front. Immunol.* 16:1593153. doi: 10.3389/fimmu.2025.1593153

In the published article, there was an error in **Supplementary Tables 1 and 2**. Several units and the order in which the baseline variables appear are written incorrectly. The supplementary material has been updated in the original article.

In the published article, there was also several errors in the text. In the **Abstract**, the hazard ratio of “1.46” was erroneous due to a typographical mistake. The accurate hazard ratio value is “1.046”.

A correction has been made to **Abstract**, *Results*, paragraph 1. This sentence previously stated:

“For both groups, the median recurrence-free survival (hazard ratio 1.46, 95%CI 0.58-1.90) and median overall survival (hazard ratio 1.06, 95%CI 0.42-2.67) were not reached, with no significant difference between the two groups.”

The corrected sentence appears below:

“For both groups, the median recurrence-free survival (hazard ratio 1.046, 95%CI 0.58-1.90) and median overall survival (hazard ratio 1.06, 95%CI 0.42-2.67) were not reached, with no significant difference between the two groups.”

In the *Results*, the hazard ratio of “1.46” was erroneous due to a typographical mistake. The accurate hazard ratio value is “1.046”.

A correction has been made to **Results**, *Comparison of RFS and OS between tislelizumab with and without TKIs group*, paragraph 6. This sentence previously stated:

“The median RFS between the tislelizumab group and the tislelizumab plus TKIs group was not reached, with no significant difference (HR 1.46, 95%CI 0.58–1.90, Figure 3A).”

The corrected sentence appears below:

“The median RFS between the tislelizumab group and the tislelizumab plus TKIs group was not reached, with no significant difference (HR 1.046, 95%CI 0.58–1.90, Figure 3A).”

The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.